UCL Drug Discovery Institute launch

The Alzheimer's Research UK UCL Drug Discovery Institute was launched at an event last Wednesday 4 May as part of the Alzheimer's Research UK Drug Discovery Alliance. Part of a network of three Institutes, the UCL Drug Discovery Institute will work with its counterparts at the Universities of Oxford and Cambridge to support the translation of cutting-edge academic science towards new treatments for dementia. The event, hosted by UCL and Alzheimer's Research UK, saw several speakers take to the stage to discuss current efforts in dementia research at the university and reflect on the importance of the charity's investment. Professor Michael Arthur, UCL's President & Provost, opened the event by speaking of the major strategic importance of the UCL Drug Discovery Institute and how it integrates with ongoing efforts taking place at the university to tackle dementia. He spoke of a historic moment where future generations will look back at the launch of these initiatives as real turning points in the fight against Alzheimer's and other dementias. Hilary Evans, Chief Executive of Alzheimer's Research UK, stressed that people are at the heart of everything the charity does and how this approach underpins our strategic efforts to couple basic and translational research to bring patient benefit more quickly. She spoke of the collaborative nature of the Alzheimer's Research UK Drug Discovery Alliance and how it will bring together the best that academia and industry has to offer.